Skip to content
Open access

High‐Resolution Diffusion Tensor Imaging of the Hippocampus and Associations With Neuropsychiatric Symptoms in Lewy Body Diseases

Sep 2026 · Hippocampus · Vol 36 · 0 citations · 94 references
Medicine

TL;DR

Lower hippocampal fractional anisotropy in the LBD spectrum relative to HC potentially reflects microstructure alterations; however, higher hippocampal FA in LBD with more severe depression suggests more complex microstructural changes such as altered synaptic density, Lewy neurite organization, or neuroplastic changes.

Abstract

Parkinson's disease (PD) encompasses motor and neuropsychiatric symptoms (NPS) including depression, anxiety, and apathy. Cognitive subtypes—PD with mild cognitive impairment (PD‐MCI) and PD with dementia (PDD)—and the related Dementia with Lewy Bodies (DLB) exist within the spectrum of Lewy body disease (LBD). While NPS are a major comorbidity, established imaging biomarkers are not available, nor is the neuronal basis well known. Additionally, prevalence of NPS may be linked to cognitive status. The hippocampus is implicated in the development of NPS and may undergo microstructural changes that are not reflected in volume changes. High‐resolution diffusion tensor imaging (DTI) was used to identify hippocampal changes in LBD compared to healthy controls (HC) and examine the relationship with NPS within the LBD group, both through association with DTI measures as well as comparison of cognitive subgroups. The hippocampus was manually segmented in 38 LB spectrum participants (aged 58–87 years, 32% female) and 35 HC (aged 50–83 years, 54% female) on high‐resolution (1 × 1 × 1 mm3) DTI. The LBD group (LBD‐All) was divided into LBD‐Cognitively Impaired (LBD‐CI) and LBD‐Cognitively Unimpaired (LBD‐CU). Hippocampal volume, mean diffusivity (MD), and fractional anisotropy (FA) were extracted and compared across groups. Relationships between significantly different hippocampal measures and depression, anxiety, and apathy were explored within the LBD‐All group. Hippocampal FA was lower in LBD‐All relative to HC; however, no differences in MD or volume were observed. Hippocampal FA was positively associated with depression scores within LBD‐All. There were no differences in volume, MD, or FA between LBD‐CI and LBD‐CU. Lower hippocampal fractional anisotropy in the LBD spectrum relative to HC potentially reflects microstructure alterations; however, higher hippocampal FA in LBD with more severe depression suggests more complex microstructural changes such as altered synaptic density, Lewy neurite organization, or neuroplastic changes.

Read PDF

Similar papers

Sep 2026

Alzheimer's Co-Pathology Burden on Basal Forebrain Atrophy and Cognitive Impairment in Dementia with Lewy Bodies: A Cross-Sectional Pilot Study.

OBJECTIVE Dementia with Lewy Bodies (DLB) is the second most common neurodegenerative dementia after Alzheimer's disease (AD), with significant pathological overlap between the two conditions. However, the impact of Alzheimer's co-pathology on basal forebrain (BF) atrophy and its relationship with neurodegeneration and...

Daniele Urso, Thomas Giannelli, B. Tafuri et al. · 0 citations
Open access Sep 2026

Hippocampal subfield diffusion abnormalities in Parkinson’s disease with mild cognitive impairment: a volumetric and diffusion MRI study

PD-MCI was characterized by distributed hippocampal diffusivity alterations despite the absence of detectable volumetric differences, and subfield-specific diffusion measures may provide complementary information on cognition-related hippocampal involvement beyond conventional volumetry.

Yu-Mei Chen, Lu Peng, Qing Hu et al. · 0 citations
Open access Sep 2026

Cerebral perfusion correlates of domain-specific cognitive function in Alzheimer's disease and dementia with Lewy bodies

Distinct patterns of cerebral perfusion-cognition relationships characterize AD and DLB, reflecting differential regional vulnerabilities underlying cognitive decline, which may contribute to improved understanding of the pathophysiology underlying cognitive decline and support disease monitoring.

Yume Koizumi, Yoshikazu Nakano, Mitsuyoshi Tamura et al. · 0 citations
Open access 2026

Parkinson’s Disease Dementia: Etiology, Mechanisms, Diagnosis, Management and Future Directions

Disease-modifying therapies remain investigational, but future directions include biological staging, precision phenotyping, synuclein-targeted immunotherapy, lysosomal enhancement, neuroinflammation modulation, digital biomarkers, and integrated trials across the Lewy body disease spectrum.

A. Abyad · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.